<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="60207">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01666535</url>
  </required_header>
  <id_info>
    <org_study_id>REMICADEIBD4010</org_study_id>
    <nct_id>NCT01666535</nct_id>
  </id_info>
  <brief_title>Infliximab IBD Influenza Vaccine Study</brief_title>
  <official_title>Effect of Influenza Vaccination Timing on Immune Response in Patients With Inflammatory Bowel Disease on Infliximab Therapy: A Randomized Equivalence Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Calgary</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Janssen Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Calgary</source>
  <oversight_info>
    <authority>Canada: Ethics Review Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators will compare the immunogenicity of influenza vaccine in adults and
      children with inflammatory bowel disease by timing of vaccine in relation to maintenance
      infliximab dosing. The primary objective is to compare the proportion of IBD patients on
      maintenance infliximab who mount serologic protection to each component of the influenza
      vaccination between patients vaccinated on day of infliximab infusion (Day 0 to 4) and
      patients vaccinated at the mid-point between infliximab infusions (Day 21 to 28).  Serologic
      protection will be defined by a hemagglutination-inhibition titer ≥ 1:40. The secondary
      objective is to compare the proportion of IBD patients who mount an immunogenic response (≥
      4-fold increase from pre to post-vaccination titer) to each component of the influenza
      vaccination between patients vaccinated on day of infliximab infusion and those vaccinated
      at the mid-point.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Anticipated">August 2013</completion_date>
  <primary_completion_date type="Anticipated">March 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Serologic protection</measure>
    <time_frame>28 days ± 3 days after influenza vaccination</time_frame>
    <safety_issue>No</safety_issue>
    <description>To compare the proportion of IBD patients on maintenance infliximab who mount serologic protection to each component of the influenza vaccination between patients vaccinated on day of infliximab infusion (Day 0 to 4) and patients vaccinated at the mid-point between infliximab infusions (Day 21 to 28).  Serologic protection will be defined by a hemagglutination-inhibition titer ≥ 1:40.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunogenic response</measure>
    <time_frame>28 days ± 3 days after influenza vaccination</time_frame>
    <safety_issue>No</safety_issue>
    <description>To compare the proportion of IBD patients on maintenance infliximab who mount an immunogenic response to each component of the influenza vaccination between patients vaccinated on day of infliximab infusion (Day 0 to 4) and patients vaccinated at the mid-point between infliximab infusions (Day 21 to 28).  Immunogenicity will be defined as a fourfold or greater differences in titer between pre and post-vaccination sera.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of participants with serious adverse events</measure>
    <time_frame>3 days post vaccination</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>To evaluate the number of participants with early serious adverse reactions (≤ 3 days post-vaccination)</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in disease activity from baseline</measure>
    <time_frame>Four week post-vaccination</time_frame>
    <safety_issue>No</safety_issue>
    <description>To evaluate the change in disease activity score from baseline using the validated instruments of the Pediatric Ulcerative Colitis Activity Index for participants with Ulcerative Coltiis and the Harvey Bradshaw Index for participants with Crohn's Disease</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Inflammatory Bowel Disease</condition>
  <arm_group>
    <arm_group_label>Influenza vaccination Timing #1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Influenza vaccination administered on the same day as infliximab administration (Day 0 to 4).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Influenza vaccination Timing #2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Influenza vaccination administered at the mid-point between infliximab infusions (Day 21 to 28)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Influenza vaccination</intervention_name>
    <arm_group_label>Influenza vaccination Timing #1</arm_group_label>
    <arm_group_label>Influenza vaccination Timing #2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of IBD established by accepted criteria

          -  On maintenance infliximab administered every 6 to 8 weeks (already received at least
             6 weeks of infliximab)

          -  Between ages 9 and 60 years

        Exclusion Criteria:

          1. Pregnancy

          2. Hypersensitivity reaction to previous dose of influenza vaccine

          3. Known hypersensitivity to eggs or chicken or other components of influenza vaccine
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>9 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jennifer deBruyn, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Calgary</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jennifer deBruyn</last_name>
    <email>jennifer.debruyn@albertahealthservices.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Calgary</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T3B 6A8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jennifer deBruyn</last_name>
      <email>jennifer.debruyn@albertahealthservices.ca</email>
    </contact>
    <investigator>
      <last_name>Jennifer deBruyn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Remo Panaccione,, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Iwona Wrobel, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cynthia Seow, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <lastchanged_date>August 10, 2012</lastchanged_date>
  <firstreceived_date>August 8, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Calgary</investigator_affiliation>
    <investigator_full_name>Jennifer deBruyn</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Influenza vaccine</keyword>
  <keyword>Immune response</keyword>
  <keyword>Remicade (infliximab)</keyword>
  <keyword>Inflammatory bowel disease</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
    <mesh_term>Influenza, Human</mesh_term>
    <mesh_term>Intestinal Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Infliximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
